Johnson & Johnson 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NYSE
Johnson & Johnson reported robust financial performance in fiscal year 2025 with 6.0% sales growth and a significant increase in earnings before taxes, while advancing its strategic plan to separate its Orthopaedics business.
NYSE
Johnson & Johnson's 2024 annual report reveals a 4.3% increase in worldwide sales, driven by growth in both Innovative Medicine and MedTech segments, alongside strategic acquisitions and R&D investments.
NYSE
10-K: Johnson & Johnson Files 10-K Report, Details Financial Performance and Strategic Outlook for 2023
Johnson & Johnson's 2023 10-K filing reveals a 6.5% increase in worldwide sales, significant investments in R&D, and a strategic shift following the separation of its Consumer Health business.